Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
188Re-EL
- Development stage
- Unknown
- Lead developer
- Korea Institute of Radiological and Medical Sciences
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intra-arterial
01
Overview
188Re-EL is a radiopharmaceutical consisting of the high-energy beta-emitting radioisotope rhenium-188 (188Re) labeled to ethiodized oil (Lipiodol), used primarily for intra-arterial radiotherapy, especially in hepatocellular carcinoma (HCC) and other liver tumors. 188Re emits beta particles (max energy 2.12 MeV) which induce local cytotoxic effects in tumor tissue, with a gamma emission (155 keV) suitable for imaging and dosimetry. Its short physical half-life (16.9 hours) enables therapeutic applications with manageable toxicity and logistical convenience due to on-demand generation from a 188W/188Re generator. The agent is delivered directly to tumor vasculature (typically by hepatic arterial route), exploiting its preferential accumulation in tumor tissue. The primary mechanism of action is targeted beta radiation-induced cell death of malignant cells at the administration site[1][3][5].
- Brand names
- 188Re-EL
- Other names
- 188Re-EL
02
Targets
DNA
Beyond the preview
Go deeper on 188Re-EL.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 188Re-EL.